## **FACT SHEET**




#### **COMPANY PROFILE**

STRATEC SE (Frankfurt: SBS; Prime Standard, ISIN: DE000STRA555) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers integrated laboratory software and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

#### SHARE CHART





### SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	40.33%
Treasury shares	0.02%
Free float	59.65%
Total	100.00%

#### MANAGEMENT BOARD



Marcus Wolfinger

Dr. Robert Siegle

Dr. Claus Vielsack

Dr. Georg Bauer

#### SUPERVISORY BOARD

Prof. Dr. Georg Heni Dr. Frank Hiller Dr. Rolf Vornhagen Dr. Patricia Geller

#### STOCK FUNDAMENTALS

ISIN DE000STRA555 WKN STRA55 Symbol SBS Reuters Code SBSG.DE Pharma & Healthcare

Transparency level Prime Standard Regulated Market Market segment Type of shares Registered Shares Registered capital 12,157,841 Euro No. of shares 12.157.841 Initial listing Aug 25, 1998

Stock exchanges Xetra; Frankfurt am Main and other regional

exchanges in Germany

Publication annual financial report

#### FINANCIAL CALENDAR

Mar 28, 2024

Apr 22, 2024	METZLER Small Cap Days Organized by: Metzler Capital Markets
Apr 26, 2024	Publication quarterly statement (call-date Q1)
May 14, 2024	Pan European Small and Mid-Cap Conference Organized by: UBS
May 15, 2024	Berenberg Diagnostics Conference Organized by: Berenberg Bank
May 17, 2024	Annual General Meeting
Jun 07, 2024	Warburg Highlights Conference Organized by: Warburg Research
Aug 09, 2024	Publication half-yearly financial report
Sep 04 - Sep 05, 2024	21st Annual Goldman Sachs European Medtech and Healthcare Conference Organized by: Goldman Sachs
Oct 25, 2024	Publication quarterly statement (call-date Q3)
Nov 26, 2024	German Equity Forum Organized by: Deutsche Börse - Analysts' Conference -

STRATEC SE Page 1 of 2

# **FACT SHEET**



## KEY FIGURES AT A GLANCE 1

IFRS (in € million)	2018	2019	2020	2021	2022
Sales	187.8	214.2	250.1	287.3	274.6
Adjusted EBIT	26.2	29.3	41.7	54.3	45.1
Adjusted EBIT margin (%)	13.9	13.7	16.7	18.9	16.4
Adjusted consolidated net income	20.2	24.1	35.2	45.1	34.7
Adjusted earnings per share (€)	1.70	2.01	2.92	3.73	2.86
Dividend per share (€)	0.82	0.84	0.90	0.95	0.97
No. of employees	1,228	1,302	1,319	1,398	1,481
Total assets	275.3	299.4	331.9	368.5	397.5
Equity ratio (%)	55.3	53.1	52.0	55.8	56.6

<sup>&</sup>lt;sup>1</sup>Figures adjusted for comparison; adjusted for depreciation and amortization from purchase price allocation for acquisitions, related integration expenses and other extraordinary effects. Reconciliation to IFRS figures can be found in the respective annual report.

STRATEC SE

Gewerbestr. 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 info@stratec.com www.stratec.com **Investor Relations** 

Phone: +49 7082 7916-6515 Fax: +49 7082 7916-9190

ir@stratec.com

STRATEC SE Page 2 of 2 Powered by: